{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:09:30Z","timestamp":1784286570097,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,28]],"date-time":"2019-12-28T00:00:00Z","timestamp":1577491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004686","name":"Deanship of Scientific Research, King Faisal University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004686","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jiph.2019.12.006","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T21:10:02Z","timestamp":1579036202000},"page":"295-298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Evaluation and characterisation of Chronic myeloid leukemia and various treatments in Saudi Arabia: A retrospective study"],"prefix":"10.1016","volume":"13","author":[{"given":"Farjah H.","family":"Algahtani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatmah S.","family":"Alqahtany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2019.12.006_bib0005","doi-asserted-by":"crossref","DOI":"10.1002\/jcp.28732","article-title":"Chronic myeloid leukemia-derived exosomes attenuate adipogenesis of adipose derived mesenchymal stem cells via transporting miR-92a-3p","author":"Wan","year":"2019","journal-title":"J Cell Physiol"},{"issue":"2","key":"10.1016\/j.jiph.2019.12.006_bib0010","first-page":"105","article-title":"Response to therapy, treatment intolerance and tyrosine kinase inhibitor cessation eligibility in a real-world cohort of chronic myeloid leukaemia patients","volume":"88","author":"McMullan","year":"2019","journal-title":"Ulster Med J"},{"issue":"7","key":"10.1016\/j.jiph.2019.12.006_bib0015","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.drudis.2019.05.007","article-title":"Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options","volume":"24","author":"Meenakshi Sundaram","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jiph.2019.12.006_bib0020","article-title":"Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options","author":"Sundaram","year":"2019","journal-title":"Drug Discov Today"},{"issue":"2","key":"10.1016\/j.jiph.2019.12.006_bib0025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.htct.2018.10.001","article-title":"Management of chronic myeloid leukemia during pregnancy: a retrospective analysis at a single center","volume":"41","author":"Moura","year":"2019","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.jiph.2019.12.006_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.htct.2018.11.005","article-title":"What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials?","author":"Bosi","year":"2019","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.jiph.2019.12.006_bib0035","first-page":"e717","article-title":"Influence of glutathione S-transferases (GSTM1, GSTT1, and GSTP1) genetic polymorphisms and smoking on susceptibility risk of chronic myeloid leukemia and treatment response","author":"Rostami","year":"2019","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.jiph.2019.12.006_bib0040","first-page":"1","article-title":"Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US","author":"Jabbour","year":"2019","journal-title":"J Med Econ"},{"issue":"2","key":"10.1016\/j.jiph.2019.12.006_bib0045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12185-017-2334-x","article-title":"Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study","volume":"107","author":"Takahashi","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jiph.2019.12.006_bib0050","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2147\/DDDT.S191303","article-title":"Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities","volume":"13","author":"Flis","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jiph.2019.12.006_bib0055","article-title":"Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy","author":"Efficace","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jiph.2019.12.006_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2019.03.028","article-title":"The outcomes of chronic myeloid leukemia patients with molecular warning responses during imatinib treatment according to the european LeukemiaNet 2013 recommendations","author":"Soysal","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jiph.2019.12.006_bib0065","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-019-03706-x","article-title":"Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life","author":"Molica","year":"2019","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.jiph.2019.12.006_bib0070","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1586\/14737140.2013.859074","article-title":"Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia","volume":"13","author":"Jabbour","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jiph.2019.12.006_bib0075","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-019-03690-2","article-title":"Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors","author":"Ren","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jiph.2019.12.006_bib0080","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.leukres.2019.04.011","article-title":"First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: age and dose still matter","volume":"81","author":"Belohlavkova","year":"2019","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.jiph.2019.12.006_bib0085","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11596-019-2021-7","article-title":"Monitoring and analysis of chinese chronic myeloid leukemia patients who have stopped tyrosine kinase inhibitor therapy","volume":"39","author":"Shen","year":"2019","journal-title":"Curr Issues Pharm Med Sci Pract"},{"issue":"3","key":"10.1016\/j.jiph.2019.12.006_bib0090","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.jiph.2019.12.006_bib0095","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology","volume":"16","author":"Radich","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jiph.2019.12.006_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2019.05.004","article-title":"Risk and outcomes of second malignant neoplasms in chronic myeloid leukemia survivors","volume":"82","author":"Jamy","year":"2019","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.jiph.2019.12.006_bib0105","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.beha.2009.07.007","article-title":"Epidemiology of chronic myeloid leukaemia (CML)","volume":"22","author":"Rohrbacher","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"issue":"14","key":"10.1016\/j.jiph.2019.12.006_bib0110","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1002\/cncr.31411","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group","volume":"124","author":"Rea","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.jiph.2019.12.006_bib0115","series-title":"IBM SPSS statistics for windows","author":"IBMCorp","year":"2016"},{"issue":"7","key":"10.1016\/j.jiph.2019.12.006_bib0120","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4065\/81.7.973","article-title":"Chronic myeloid leukemia: diagnosis and treatment","volume":"81","author":"Quintas-Cardama","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1016\/j.jiph.2019.12.006_bib0125","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/cncr.22523","article-title":"Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jiph.2019.12.006_bib0130","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12185-008-0230-0","article-title":"Chronic myeloid leukemia in Asia","volume":"89","author":"Au","year":"2009","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.jiph.2019.12.006_bib0135","first-page":"7","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.jiph.2019.12.006_bib0140","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.hoc.2004.03.011","article-title":"Natural history and staging of chronic myelogenous leukemia","volume":"18","author":"Cortes","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jiph.2019.12.006_bib0145","series-title":"CHRONIC MYELOGENOUS LEUKEMIA review of Cancer medicines on the WHO list of essential medicines","author":"Control, U.f.I.C","year":"2014"},{"key":"10.1016\/j.jiph.2019.12.006_bib0150","unstructured":"CancerStatFacts.(n.d.). Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html."},{"key":"10.1016\/j.jiph.2019.12.006_bib0155","unstructured":"Society, A.c. Key Statistics for Chronic Myeloid Leukemia. Available from: https:\/\/www.cancer.org\/cancer\/chronic-myeloid-leukemia\/about\/statistics.html."},{"issue":"8","key":"10.1016\/j.jiph.2019.12.006_bib0160","first-page":"469","article-title":"Presentating phases of chronic myeloid leukaemia","volume":"19","author":"Ahmed","year":"2009","journal-title":"J Coll Physicians Surg Pak"},{"issue":"3","key":"10.1016\/j.jiph.2019.12.006_bib0165","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4103\/0971-5851.123719","article-title":"Report of chronic myeloid leukemia from Indira Gandhi Institute of Medical Sciences, regional Cancer center, 2002-2009","volume":"34","author":"Prasad","year":"2013","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"6","key":"10.1016\/j.jiph.2019.12.006_bib0170","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/sj.leu.2403756","article-title":"Gender aspects in chronic myeloid leukemia: long-term results from randomized studies","volume":"19","author":"Berger","year":"2005","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jiph.2019.12.006_bib0175","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00411-013-0507-4","article-title":"Sex differences in the incidence of chronic myeloid leukemia","volume":"53","author":"Radivoyevitch","year":"2014","journal-title":"Radiat Environ Biophys"},{"issue":"23","key":"10.1016\/j.jiph.2019.12.006_bib0180","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2019.12.006_bib0185","unstructured":"Society, A.C.; Available from: https:\/\/www.cancer.org\/cancer\/chronic-myeloid-leukemia\/detection-diagnosis-staging\/survival-rates.html19%20June%202018."}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034119303879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034119303879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:04:58Z","timestamp":1761750298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034119303879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1876034119303879"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2019.12.006","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation and characterisation of Chronic myeloid leukemia and various treatments in Saudi Arabia: A retrospective study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2019.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}